NCT03799718View on ClinicalTrials.gov

Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

March 13, 2019

Primary Completion Date

March 11, 2021

Study Completion Date

March 30, 2021

Conditions
Multiple Sclerosis, Chronic Progressive
Interventions
BIOLOGICAL

NurOwn (MSC-NTF cells)

Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors

Trial Locations (4)

10029

The Mount Sinai Hospital, New York

44195

Cleveland Clinic, Cleveland

90033

University of Southern California, Los Angeles

94305

Stanford University School of Medicine, Redwood City

Sponsors
All Listed Sponsors
lead

Brainstorm-Cell Therapeutics

INDUSTRY